Emergent BioSolutions stockholders elect three Class I directors, ratify auditor, approve advisory compensation

Emergent BioSolutions Inc.

Annual meeting held April 30, 2025; 36,140,808 shares (67% of outstanding) present.
Class I directors Keith Katkin, Ronald Richard, Kathryn Zoon each elected with >18M votes for.
Ernst & Young ratified as independent auditor for FY2025 with 34,773,959 for, 1,152,704 against.
Advisory vote on named executive officer compensation approved with 18,928,777 for, 3,537,501 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.